⚠️ Research Use Only — This product is intended for in vitro research purposes only. Not for human consumption or clinical use. Consult a licensed physician for medical advice.

All products are supplied for laboratory and research purposes only. Not for human consumption or clinical use. No statement on this website has been evaluated by BPOM, the FDA, or any health authority. Not intended to diagnose, treat, cure, or prevent any disease. All trial figures below are reported from published clinical literature and describe study subjects, not customers.

Retatrutide in Bali: Triple-Agonist Research Peptide

Retatrutide (LY3437943) is a novel triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. Clinical trials have demonstrated unprecedented weight loss outcomes, making it a compound of significant research interest in metabolic science.

What is Retatrutide?

Retatrutide is a synthetic peptide developed by Eli Lilly as an investigational compound studied in obesity and type 2 diabetes research. Unlike earlier GLP-1 receptor agonists (semaglutide, liraglutide) or dual agonists (tirzepatide), retatrutide simultaneously activates three distinct metabolic pathways:

• GLP-1 receptor agonism → Enhances insulin secretion, suppresses glucagon, delays gastric emptying
• GIP receptor agonism → Amplifies insulin response, may improve fat metabolism and satiety
• Glucagon receptor agonism → Increases energy expenditure, promotes fat oxidation, reduces hepatic lipid accumulation

This triple-agonist mechanism represents a distinct approach from current GLP-1 monotherapies and GLP-1/GIP dual agonists.

Clinical Trial Data (Phase 2)

The landmark Phase 2 trial published by Jastreboff et al. (2023) in the New England Journal of Medicine evaluated retatrutide in 338 adults with obesity over 48 weeks:

The 12 mg dose cohort achieved a mean weight reduction of 24.2% at 48 weeks—the highest ever reported in a clinical trial for any pharmacological obesity intervention. For context:

• Semaglutide (Wegovy 2.4 mg): ~15% weight loss at 68 weeks
• Tirzepatide (Zepbound 15 mg): ~22% weight loss at 72 weeks
• Retatrutide 12 mg: ~24% weight loss at 48 weeks

Mechanism: Why Three Receptors?

The addition of glucagon receptor agonism to the GLP-1/GIP framework is the key differentiator. While glucagon is traditionally associated with raising blood glucose, when combined with GLP-1 and GIP in retatrutide's engineered peptide sequence:

• Energy expenditure increases → Glucagon receptor activation in adipose tissue promotes thermogenesis and fat oxidation
• Hepatic fat clearance → Reduces steatosis without elevating blood glucose (GLP-1 counterbalances glucagon's glycemic effects)
• Enhanced lipolysis → Mobilizes stored fat more aggressively than GLP-1 alone

This synergistic effect explains why retatrutide outperforms dual agonists in preclinical models and early human trials.

Research Applications

Retatrutide is being investigated for:

• Obesity pharmacotherapy — Mechanisms of unprecedented weight loss via triple-agonism
• Metabolic syndrome — Effects on insulin sensitivity, lipid profiles, and hepatic steatosis
• Type 2 diabetes — Glycemic control beyond current incretin therapies
• NASH/NAFLD — Glucagon's role in hepatic fat metabolism
• Cardiovascular outcomes — Ongoing Phase 3 trials (TRIUMPH program) examining CV safety and outcomes

Dosing Protocols (Research Context)

Clinical trials used a dose-escalation protocol to minimize gastrointestinal side effects:

• Weeks 1-4: 2 mg subcutaneous once weekly
• Weeks 5-8: 4 mg once weekly
• Weeks 9-12: 8 mg once weekly
• Week 13+: 12 mg once weekly (maintenance dose)

Gradual titration reduced discontinuation rates due to nausea, vomiting, and diarrhea (common with all GLP-1 agonists). Even at 12 mg, retatrutide's tolerability profile was comparable to lower-dose semaglutide.

Comparison: Retatrutide vs. Semaglutide vs. Tirzepatide

Retatrutide achieved greater weight loss in less time, suggesting accelerated fat loss via glucagon-mediated energy expenditure.

Side Effect Profile

Like all GLP-1 receptor agonists, retatrutide's most common adverse effects are gastrointestinal:

• Nausea (most common in escalation phase)
• Diarrhea
• Vomiting
• Constipation

In the Phase 2 trial, GI side effects were dose-dependent but manageable with gradual titration. Serious adverse events were rare (~1% across all doses).

Availability in Indonesia

Retatrutide is currently investigational and not approved by BPOM (Indonesia's drug regulatory authority) or the FDA. It is legal to purchase research-grade peptides in Indonesia for non-human, in vitro research purposes.

BioRelix supplies research-grade retatrutide synthesized by third-party laboratories with HPLC purity verification (≥98%). Our product is:

• Not manufactured by Eli Lilly
• Not a pharmaceutical-grade drug
• Not approved for clinical use in humans
• Intended solely for in vitro research

Storage and Reconstitution

Retatrutide is supplied as lyophilized powder and requires reconstitution with bacteriostatic water:

• Unreconstituted: Store at 2-8°C (refrigerator) or -20°C (freezer for long-term storage)
• Reconstituted: Store at 2-8°C, use within 28 days
• Avoid: Freezing after reconstitution, exposure to light, temperature fluctuations

For detailed reconstitution instructions, see our Peptide Reconstitution Guide.

Research Context: What's Next for Retatrutide?

Eli Lilly's Phase 3 TRIUMPH program is currently enrolling participants for cardiovascular outcomes and obesity research trials. If successful, retatrutide could receive FDA approval as early as 2026-2027. Until then, it remains an investigational compound available only for research purposes.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
2. Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396.
3. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.
4. Brandt SJ, Götz A, Tschöp MH, Müller TD. Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides. 2018;100:190-201.

⚠️ Reminder: This product is for research use only. Not for human consumption or clinical use. Always consult a licensed physician for medical advice regarding obesity, diabetes, or metabolic conditions.